Teladoc, Inc. (NYSE:TDOC) insider Adam C. Vandervoort sold 53,806 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $30.92, for a total value of $1,663,681.52. Following the completion of the transaction, the insider now owns 33,008 shares of the company’s stock, valued at $1,020,607.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Teladoc, Inc. (TDOC) traded down 2.16% during mid-day trading on Friday, reaching $29.50. The company had a trading volume of 485,628 shares. The stock’s market capitalization is $1.67 billion. The company’s 50-day moving average is $33.13 and its 200-day moving average is $27.90. Teladoc, Inc. has a one year low of $14.00 and a one year high of $36.90.
Teladoc (NYSE:TDOC) last announced its quarterly earnings data on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.02. Teladoc had a negative net margin of 47.75% and a negative return on equity of 19.88%. The firm had revenue of $44.60 million for the quarter, compared to the consensus estimate of $44.39 million. During the same period last year, the company posted ($0.38) earnings per share. Teladoc’s revenue for the quarter was up 68.3% on a year-over-year basis. Equities research analysts anticipate that Teladoc, Inc. will post ($1.44) earnings per share for the current year.
TDOC has been the subject of a number of analyst reports. Zacks Investment Research downgraded Teladoc from a “hold” rating to a “sell” rating in a research note on Tuesday, May 2nd. Chardan Capital raised their price target on Teladoc from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, May 9th. Robert W. Baird restated a “buy” rating and issued a $28.00 price target on shares of Teladoc in a research note on Tuesday, May 9th. Craig Hallum downgraded Teladoc from a “buy” rating to a “hold” rating and raised their price target for the company from $28.00 to $32.00 in a research note on Friday, May 12th. Finally, KeyCorp assumed coverage on Teladoc in a research report on Wednesday, May 17th. They issued an “overweight” rating and a $37.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $35.55.
Large investors have recently bought and sold shares of the company. US Bancorp DE increased its stake in Teladoc by 10.3% in the first quarter. US Bancorp DE now owns 4,617 shares of the health services provider’s stock valued at $116,000 after buying an additional 433 shares in the last quarter. Jaffetilchin Investment Partners LLC increased its stake in Teladoc by 1.8% in the first quarter. Jaffetilchin Investment Partners LLC now owns 45,225 shares of the health services provider’s stock valued at $1,131,000 after buying an additional 814 shares in the last quarter. Teachers Advisors LLC increased its stake in Teladoc by 5.3% in the fourth quarter. Teachers Advisors LLC now owns 35,205 shares of the health services provider’s stock valued at $581,000 after buying an additional 1,759 shares in the last quarter. Rosenblum Silverman Sutton S F Inc. CA increased its stake in Teladoc by 2.7% in the second quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 67,395 shares of the health services provider’s stock valued at $2,339,000 after buying an additional 1,800 shares in the last quarter. Finally, Bank of Montreal Can increased its stake in Teladoc by 214.2% in the second quarter. Bank of Montreal Can now owns 3,516 shares of the health services provider’s stock valued at $123,000 after buying an additional 2,397 shares in the last quarter. Hedge funds and other institutional investors own 94.51% of the company’s stock.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.